Study ID | Intervention(s) and comparator(s) | Participants included in analysis (N) | Deaths (N) | Deaths (%) | Participants with at least one adverse event (N) | Participants with at least one adverse event (%) | Participants with at least one severe/serious adverse event (N) | Participants with at least one severe/serious adverse event (%) |
Timmers 2016 (cross‐over RCT) |
I: trans‐resveratrol + oral hypoglycaemic agent(s) or diet alone | 17 | 0 | 0 | 0 | 0 | 0 | 0 |
C: placebo + oral hypoglycaemic agent(s) or diet alone | 17 | 0 | 0 | 0 | 0 | 0 | 0 | |
Thazhath 2016 (cross‐over RCT) |
I: resveratrol | 14 | 0 | 0 | 0 | 0 | 0 | 0 |
C: placebo | 14 | 0 | 0 | 0 | 0 | 0 | 0 | |
Brasnyo 2011 (parallel RCT) |
I: trans‐resveratrol | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
C: placebo | 9 | 0 | 0 | 0 | 0 | 0 | 0 | |
— denotes not reported. C: comparator, I: intervention, N: number of participants. |